| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
JR14a cells, whose IC50 ranges from 0.1 nM to 100 μM, have been shown to block C3a-induced internal Ca2+ release in human monocyte-derived macrophages[1]. An IC50 of 8 nM is observed in human LAD2 mast cells exposed to intravenous injection of JR14a (0.1 nM-100 μM) to inhibit C3a β-hexosaminidase [1].
|
|---|---|
| ln Vivo |
JR14a (10 mg/kg; po 2 h before) induced 65% more paw swelling than controls 30 minutes after hemostatic injection in an acute state paw model of edema and edema [1]. JR14a (1 mg/kg; iv) exhibited elimination half-life (191 minutes), clearance (4.4 mL/min/kg), and AUC (3795 ng·h/mL) at shelf [1]. JR14a (10 mg/kg; po) exhibited Cmax (88 ng/mL), Tmax (300 min), and AUC (478 ng h/mL) at shelf [1].
|
| Animal Protocol |
Animal/Disease Models: Male Wister rats (8 weeks, 250-300 g) were injected with BR103[1].
Doses: 10 mg/kg Route of Administration: Oral 2 hrs (hrs (hours)) before agonist challenge Experimental Results: Inhibits C3aR-mediated inflammation. Animal/Disease Models: Male Wister rat (8 weeks, 250-300 g) [1] Doses: 1 mg/kg, intravenous (iv) (iv)injection; oral 10 mg/kg (pharmacokinetic/PK/PK analysis) Route of Administration: intravenous (iv) (iv)administration and oral administration Dosing Experimental Results: IV: t1/2=191 min, clearance=4.4 mL/min/kg, AUC=3795 ng·h/mL. Po: Cmax=88 ng/mL, Tmax=300 minutes, AUC=478 ng·h/mL. |
| References |
| Molecular Formula |
C25H26CL2N4O3S
|
|---|---|
| Molecular Weight |
533.469942569733
|
| Exact Mass |
532.11
|
| CAS # |
2411440-41-8
|
| Related CAS # |
2417323-15-8 (TFA);2411440-41-8;
|
| PubChem CID |
145996525
|
| Appearance |
White to light yellow solid powder
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
35
|
| Complexity |
716
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
ClC1C=CC(=CC=1)C(C1C=CC(=CC=1)Cl)C1=CC(C)=C(C(N[C@H](C(=O)O)CCC/N=C(\N)/N)=O)S1
|
| InChi Key |
OHRIKWUZKGNQKQ-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C25H26Cl2N4O3S/c1-14-13-20(21(15-4-8-17(26)9-5-15)16-6-10-18(27)11-7-16)35-22(14)23(32)31-19(24(33)34)3-2-12-30-25(28)29/h4-11,13,19,21H,2-3,12H2,1H3,(H,31,32)(H,33,34)(H4,28,29,30)/t19-/m0/s1
|
| Chemical Name |
(2S)-2-[[5-[bis(4-chlorophenyl)methyl]-3-methylthiophene-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~187.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (4.69 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8745 mL | 9.3726 mL | 18.7452 mL | |
| 5 mM | 0.3749 mL | 1.8745 mL | 3.7490 mL | |
| 10 mM | 0.1875 mL | 0.9373 mL | 1.8745 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
